Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of lead-induced tricuspid regurgitation.

HeartRhythm case reports·2017
Same author

Response: Electrocardiographic Markers in Patients With Takotsubo Cardiomyopathy.

Journal of cardiothoracic and vascular anesthesia·2016
Same author

Cardiogenic Shock as a Complication of Takotsubo Cardiomyopathy in a Patient With Incarcerated Bowel.

Journal of cardiothoracic and vascular anesthesia·2016
Same author

Phenotypic analysis of arrhythmogenic cardiomyopathy in the Hutterite population: role of electrocardiogram in identifying high-risk desmocollin-2 carriers.

Journal of the American Heart Association·2014
Same author

Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2014
Same author

The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study.

BMC cardiovascular disorders·2014
Same journal

Neighborhood-Level Material Resources and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease.

The Canadian journal of cardiology·2026
Same journal

Storm Clouds Coming: Red-Flag Warning for Hypertension Prevalence and Control in the Post-COVID-19 Era.

The Canadian journal of cardiology·2026
Same journal

Universal coverage, unequal care: Why Canada needs a national cardiovascular access ledger.

The Canadian journal of cardiology·2026
Same journal

Prolonged Loop Recorder Retention: Safety, Diagnostic Yield, and the Case for Community-Based Explantation.

The Canadian journal of cardiology·2026
Same journal

Multimodality Fusion Imaging of Subclinical Systemic Right Ventricular Remodeling in Congenitally Corrected Transposition of the Great Arteries.

The Canadian journal of cardiology·2026
Same journal

Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Implantation: A Bayesian Meta-Analysis of Randomized Controlled Trials.

The Canadian journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Nesiritide: the clinical experience.

Sarah G Weeks1

  • 1Department of Cardiac Sciences, Division of Cardiology, University of Calgary, Calgary, Alberta.

The Canadian Journal of Cardiology
|July 17, 2008
PubMed
Summary
This summary is machine-generated.

Nesiritide effectively reduces symptoms and filling pressures in acute decompensated heart failure patients. Health Canada

Related Experiment Videos

Last Updated: Jul 3, 2026

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Acute decompensated heart failure (ADHF) is a critical condition requiring effective therapeutic interventions.
  • Nesiritide, a B-type natriuretic peptide, has emerged as a potential treatment option for ADHF.

Purpose of the Study:

  • To summarize existing clinical trials on nesiritide for ADHF management.
  • To review the clinical experience, including indications, contraindications, dosage, and monitoring of nesiritide.

Main Methods:

  • Systematic review and summarization of published clinical trials involving nesiritide in ADHF.
  • Compilation of clinical experience data regarding nesiritide's application in heart failure.

Main Results:

  • Nesiritide demonstrates efficacy in decreasing symptoms associated with ADHF.
  • The therapy effectively reduces left ventricular filling pressures in patients with ADHF.
  • Health Canada has approved nesiritide for managing this patient population.

Conclusions:

  • Nesiritide is an effective therapeutic agent for ADHF.
  • This review provides a guide for the clinical application of nesiritide, covering essential aspects of its use.